Opendata, web and dolomites

InDx SIGNED

InDx - an innovative implant that restores natural motion to patients with thumb base joint arthritis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 InDx project word cloud

Explore the words cloud of the InDx project. It provides you a very rough idea of what is the project "InDx" about.

accommodate    causes    fda    anatomy    estimates    surgical    million    prepare    international    stage    socioeconomic    start    germany    world    extensive    validate       debilitating    expertise    irish    lags    implant    dexterity    functional    indx    movement    investigations    market    joint    namsa    company    ireland    organization    25    first    population    station    treatment    clinical    date    base    national    cumulative    university    revenues    approval    final    designed    orthopaedics    galway    implants    joints    fundamental    disruptive    running    marking    prone    biomechanics    jar    dynamic    door    medvie    europeans    arthritis    usa    commercialisation    approximately    commercialization    24    launch    employment    ce    substantial    human    51m    innovation    510k    loci    suffers    uk    natural    opening    led    months    healthcare    sme    ftes    medical    thumb    restore    burden    impossible    small    spin    humanitarian    stages    endolab    dressed    trl   

Project "InDx" data sheet

The following table provides information about the project.

Coordinator
LOCI ORTHOPAEDICS LIMITED 

Organization address
address: UNIT 209 NUIG BUSINESS INNOVATION CENTRE UPPER NEWCASTLE
city: GALWAY
postcode: H91 V207
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 3˙633˙125 €
 EC max contribution 2˙543˙187 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LOCI ORTHOPAEDICS LIMITED IE (GALWAY) coordinator 1˙746˙500.00
2    NORTH AMERICAN SCIENCE ASSOCIATES LIMITED UK (SELBY) participant 319˙812.00
3    Medvie Limited IE (MALAHIDE) participant 280˙000.00
4    ENDOLAB MECHANICAL ENGINEERING GMBH DE (RIEDERING) participant 196˙875.00

Map

 Project objective

The thumb base joint is fundamental for human dexterity and functional activity but is prone to debilitating arthritis. Approximately 5% of the world population suffers from this condition with over 25 million Europeans affected. Simple tasks become impossible such as getting dressed, opening a jar, using a key to open a door. This is certainly a relevant socioeconomic and humanitarian concern, which causes a substantial cost burden on healthcare systems, yet the effective treatment for end-stage thumb base arthritis lags far behind other joints, given challenges of the small, complex anatomy. The InDx project aims to enable the commercialization of the InDx implant, the world’s first implant designed to accommodate the complex biomechanics of the thumb base joint and restore the natural movement of the thumb. The consortium is led by Loci Orthopaedics, a technology-driven SME spin-out company from the National University of Ireland, Galway. The partners include EndoLab in Germany, that has developed a novel dynamic test station for implants, NAMSA in the UK, a leading medical research organization with extensive experience in running international clinical investigations, and Medvie, an Irish based SME with extensive project management, dissemination and commercialization expertise. Together, the consortium have brought the implant to TRL 6 level. As part of the InDx project, the consortium will undertake the final stages of product development and will validate clinical results in a clinical study that will prepare the CE marking and market access. Market launch is planned within 24 months from the project start date, following FDA 510K approval in the USA and CE marking in Europe. The consortium estimates cumulative revenues of €51M within 5 years from the start of commercialisation and an employment growth of 25 FTEs for the consortium partners. The InDx has the potential to be a disruptive innovation in the surgical management of thumb base joint arthritis.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INDX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INDX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

PATH-TOX (2018)

Artificial Intelligence to transform Drug and Chemical safety testing

Read More  

De-RISC (2019)

De-RISC: Dependable Real-time Infrastructure for Safety-critical Computer

Read More  

ENHANCEplayer (2018)

An Artificial Intelligence Enhancing Video Quality Locally to Limit Internet Traffic Tied to Video Streaming

Read More